TY - JOUR
T1 - Myocarditis or acute myocardial infarction associated with interleukin‐2 therapy for cancer
AU - Kragel, Amy H.
AU - Travis, William D.
AU - Steis, Ronald G.
AU - Rosenberg, Steven A.
AU - Roberts, William C.
PY - 1990/10/1
Y1 - 1990/10/1
N2 - The hearts of eight patients aged 22 to 67 years (mean, 41 years) who died during or within 4 days of interleukin‐2 (IL‐2) based immunotherapy for treatment of renal cell carcinoma or melanoma were studied at necropsy. Death resulted from combined cardiorespiratory failure in two patients, sepsis in four patients, acute myocardial infarction in one patient, and myocarditis in one patient. Transmural left ventricular necrosis was present in one of the two patients with significant atherosclerotic coronary artery narrowing. Noninfectious myocarditis was present in five patients: the inflammatory infiltrate was lymphocytic in four and composed of a mixture of eosinophils and lymphocytes in one. Although treatment‐related deaths associated with high‐dose IL‐2 therapy are uncommon (1.5% in 652 consecutive patients), the potential for significant myocardial ischemia or myocarditis exists, and careful monitoring for arrhythmias or myocardial failure is warranted.
AB - The hearts of eight patients aged 22 to 67 years (mean, 41 years) who died during or within 4 days of interleukin‐2 (IL‐2) based immunotherapy for treatment of renal cell carcinoma or melanoma were studied at necropsy. Death resulted from combined cardiorespiratory failure in two patients, sepsis in four patients, acute myocardial infarction in one patient, and myocarditis in one patient. Transmural left ventricular necrosis was present in one of the two patients with significant atherosclerotic coronary artery narrowing. Noninfectious myocarditis was present in five patients: the inflammatory infiltrate was lymphocytic in four and composed of a mixture of eosinophils and lymphocytes in one. Although treatment‐related deaths associated with high‐dose IL‐2 therapy are uncommon (1.5% in 652 consecutive patients), the potential for significant myocardial ischemia or myocarditis exists, and careful monitoring for arrhythmias or myocardial failure is warranted.
UR - http://www.scopus.com/inward/record.url?scp=0025149243&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025149243&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19901001)66:7<1513::AID-CNCR2820660713>3.0.CO;2-X
DO - 10.1002/1097-0142(19901001)66:7<1513::AID-CNCR2820660713>3.0.CO;2-X
M3 - Article
C2 - 2208002
AN - SCOPUS:0025149243
SN - 0008-543X
VL - 66
SP - 1513
EP - 1516
JO - Cancer
JF - Cancer
IS - 7
ER -